Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.

Tune L, Coyle JT.

Psychopharmacology (Berl). 1981;75(1):9-15.

PMID:
6117922
2.

Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.

Tune L, Coyle JT.

Arch Gen Psychiatry. 1980 Mar;37(3):293-7.

PMID:
6102457
3.

Radio receptor assay of serum neuroleptic levels in psychiatric patients.

Krska J, Sampath G, Shah A, Soni SD.

Br J Psychiatry. 1986 Feb;148:187-93.

PMID:
2870755
4.

Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.

Gaffney GR, Tune LE.

J Clin Psychiatry. 1985 Oct;46(10):428-9.

PMID:
2864332
5.

Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.

Hitri A, Craft RB, Sethi R, Sinha D.

Clin Neuropharmacol. 1987 Jun;10(3):261-71.

PMID:
2900683
6.

Anticholinergic activity in the serum of patients receiving maintenance amitriptyline or doxepin therapy.

Aaltonen L, Syvälahti E, Iisalo E, Peltomäki T.

Acta Pharmacol Toxicol (Copenh). 1985 Jan;56(1):75-80.

PMID:
3976405
7.

Risperidone plasma levels, clinical response and side-effects.

Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. Epub 2004 Nov 29.

PMID:
15565299
8.

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.

Meszaros K, Lenzinger E, Hornik K, Schönbeck G, Hatzinger R, Langer G, Sieghart W, Aschauer HN.

Neuropsychobiology. 1997;36(2):69-72.

PMID:
9267855
9.

Relationship between extrapyramidal symptoms and serum anticholinergic levels in treated chronic schizophrenics.

Bamrah JS, Krska J, Soni SD.

J Psychopharmacol. 1988 Jan;2(1):39-46. doi: 10.1177/026988118800200107.

PMID:
22159668
10.
11.

Screening for cognitive toxicity of anticholinergic drugs.

Katz IR, Greenberg WM, Barr GA, Garbarino C, Buckley P, Smith D.

J Clin Psychiatry. 1985 Aug;46(8):323-6.

PMID:
2862135
12.

Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.

Tune LE, Creese I, DePaulo JR, Slavney PR, Snyder SH.

J Nerv Ment Dis. 1981 Jan;169(1):60-3.

PMID:
6108981
13.
14.

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA.

J Clin Psychiatry. 1998 Feb;59(2):69-75.

PMID:
9501888
15.

Treatment of acute neuroleptic-induced movement disorders.

Tonda ME, Guthrie SK.

Pharmacotherapy. 1994 Sep-Oct;14(5):543-60. Review.

16.
17.

Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.

Lindenmayer JP, Smith D, Katz I.

J Clin Psychiatry. 1984 Mar;45(3):117-9.

PMID:
6142035
18.

Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs.

Menkes DB, Clarkson HO, Caradoc-Davies G, Mullen PE.

Int Clin Psychopharmacol. 1987 Jan;2(1):55-67.

PMID:
2889760
19.

A controlled trial of amantadine in drug-induced extrapyramidal disorders.

DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE.

Arch Gen Psychiatry. 1976 May;33(5):599-602.

PMID:
5066
20.

Supplemental Content

Support Center